60 related articles for article (PubMed ID: 26646859)
21. Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching.
Jørgensen J; Mungapen L; Kefalas P
J Mark Access Health Policy; 2019; 7(1):1573164. PubMed ID: 30774785
[No Abstract] [Full Text] [Related]
22. Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples.
Capozzi M; De Divitiis C; Ottaiano A; Teresa T; Capuozzo M; Maiolino P; Botti G; Tafuto S; Avallone A;
Front Public Health; 2018; 6():291. PubMed ID: 30370266
[No Abstract] [Full Text] [Related]
23. Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System.
Eriksson I; von Euler M; Malmström RE; Godman B; Wettermark B
Appl Health Econ Health Policy; 2019 Feb; 17(1):93-101. PubMed ID: 30284150
[TBL] [Abstract][Full Text] [Related]
24. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
Trifirò G; Gini R; Barone-Adesi F; Beghi E; Cantarutti A; Capuano A; Carnovale C; Clavenna A; Dellagiovanna M; Ferrajolo C; Franchi M; Ingrasciotta Y; Kirchmayer U; Lapi F; Leone R; Leoni O; Lucenteforte E; Moretti U; Mugelli A; Naldi L; Poluzzi E; Rafaniello C; Rea F; Sultana J; Tettamanti M; Traversa G; Vannacci A; Mantovani L; Corrao G
Drug Saf; 2019 Mar; 42(3):347-363. PubMed ID: 30269245
[TBL] [Abstract][Full Text] [Related]
25. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
[TBL] [Abstract][Full Text] [Related]
26. Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.
Piatkiewicz TJ; Traulsen JM; Holm-Larsen T
Pharmacoecon Open; 2018 Jun; 2(2):109-123. PubMed ID: 29623619
[TBL] [Abstract][Full Text] [Related]
27. Association of neovascular age-related macular degeneration with month and season of birth in Italy.
Longo A; Casuccio A; Pani L; Avitabile T; Cillino S; Uva MG; Bonfiglio V; Russo A; Parisi G; Cennamo G; Furino C; Parravano M; Xoxi E; Reibaldi M
Aging (Albany NY); 2016 Dec; 9(1):133-141. PubMed ID: 27997361
[TBL] [Abstract][Full Text] [Related]
28. Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?
Garattini L; Curto A
Pharmacoeconomics; 2016 Oct; 34(10):967-9. PubMed ID: 27260615
[No Abstract] [Full Text] [Related]
29. IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT.
Facey K; Henshall C; Sampietro-Colom L; Thomas S
Int J Technol Assess Health Care; 2015 Jan; 31(4):201-6. PubMed ID: 26646858
[TBL] [Abstract][Full Text] [Related]
30. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
31. Pharmacovigilance in Italy: An overview.
Mazzitello C; Esposito S; De Francesco AE; Capuano A; Russo E; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S20-8. PubMed ID: 24347976
[TBL] [Abstract][Full Text] [Related]
32. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
33. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
34. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
35. Access in all areas? a round up of developments in market access and health technology assessment: part 4.
Beattie A; Treharne C; Ramagopalan SV
J Comp Eff Res; 2024 Jun; 13(6):e240060. PubMed ID: 38647164
[TBL] [Abstract][Full Text] [Related]
36. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
